ACTIVE HALF-LIFE
5 days
CLASSIFICATION
Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER
Beligas - US
WAREHOUSE
USA Warehouse 2
SUBSTANCE
GIP/GLP-1 RA
Introducing Tirzepatide, a groundbreaking synthetic peptide designed to effectively lower glucose levels in the body. This innovative solution works by stimulating both the initial and secondary phases of insulin release while simultaneously reducing glucagon levels?its efficacy is dependent on glucose availability.
For individuals with type 2 diabetes, Tirzepatide has shown remarkable results in slowing gastric emptying, lowering fasting and post-meal glucose levels, curbing appetite, and facilitating weight loss. It also plays a vital role in enhancing insulin sensitivity.
The peptide's unique structure features a C20 fatty diacid linked via a hydrophilic connection at the lysine residue located at position 20, which results in a robust binding to albumin in the bloodstream, effectively prolonging its action.
Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are present throughout the body, particularly in pancreatic beta-cells and the gastrointestinal tract. These receptors are crucial in managing type II diabetes mellitus, as GLP-1R signaling supports glucose regulation by stimulating insulin release in response to glucose, decelerating gastric emptying, reducing blood glucagon levels, and activating brain pathways that help suppress appetite. Additionally, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are key hormones that work together to regulate glucose levels by promoting insulin secretion from pancreatic beta-cells, with GIP serving as the primary incretin hormone that sparks insulin release upon food intake.
While the precise mechanisms of Tirzepatide remain under investigation, its dual action on GIP and GLP-1R is believed to significantly contribute to its effectiveness in controlling blood sugar and managing weight. Research suggests that combining GIP with a GLP-1R agonist yields a stronger insulin response and a more significant reduction in glucagon secretion compared to administering each hormone individually. Tirzepatide exhibits high affinity for both GIP and GLP-1R, demonstrating binding affinity to GIP receptors akin to that of natural GIP, while its affinity for GLP-1R is five times lower than that of native GLP-1. By effectively activating the GLP-1R signaling pathway, Tirzepatide stimulates insulin release in response to glucose through interactions with either the GIP receptor (GIPR) or the GLP-1R. However, the full implications of GIPR activation in the drug's mechanism warrant further exploration, as existing evidence on its effects on blood glucose and weight management in both preclinical and clinical environments varies.